TPI Enterprises buys European opiate pharmaceuticals company

Company News

by Jessica Amir

TPI Enterprises (ASX:TPE) has signed an agreement to buy the opiates and tableting division of a European opiate pharmaceuticals company.

The Australian poppy processing company inked the deal to buy the division of Vistin Pharma ASA in Norway for $25.4 million.

The acquisition is expected to be EPS accretive on a pro-forma NPAT basis in FY18 of 10 cents per share.

The purchase has an implied EBITDA multiple of 5.6 times for FY17.

The company says it’s a major step toward delivering its Narcotic raw material volume growth.

Shares in TPI Enterprises (ASX:TPE) are trading 10 per cent higher to $2.42.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.